Skip to main content

Table 2 Patients treated with caspofungin

From: Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry

Type of use

Monotherapy

(N = 36)

Combination therapy

(N = 6)

Total

(N = 42)

Caspofungin first-line therapy*

10 (28%)

1 (17%)

11 (26%)

Caspofungin second-line therapy**

26 (72%)

5 (83%)

31 (74%)

   Thereof reason for switching to caspofungin

   Clinically refractory to first-line therapy

21 (58%)

5 (83%)

26 (62%)

   Toxicity with first-line therapy

2 (6%)

0

2 (5%)

   Other**

3 (8%)

0

3 (7%)

  1. *The reason for using caspofungin as the first line therapy was "probable aspergillosis" in 10 patients and "proven aspergillosis" in 1 patient.
  2. **In 25 patients, this consisted of azoles (9 posaconazole, 7 voriconazole, 6 fluconazole (of these, 5 for prophylactic use and 1 for unknown reasons), 3 itraconazole), in 5 patients polyenes (2 amphotericin colloidal dispersion, 3 liposomal amphotericin B), and in 1 patient other antimycotics. Prior antimycotic therapy had been given for a mean duration of 13.2 days.
  3. **Breakthrough infection during azole prophylaxis